[1] J. VINCENT. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.[J]. British journal of clinical pharmacology, 1988, 26 5: 497-502. DOI:
10.1111/j.1365-2125.1988.tb05288.x[2] KWANG-HYEON LIU. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.[J]. Drug Metabolism and Disposition, 2006, 34 11: 1793-1797. DOI:
10.1124/dmd.106.010488[3] SHIGERU HISHINUMA . Asp73-dependent and -independent regulation of the affinity of ligands for human histamine H1 receptors by Na+[J]. Biochemical pharmacology, 2017, 128: Pages 46-54. DOI:
10.1016/j.bcp.2016.12.021[4] I YAKUO. [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist].[J]. Folia Pharmacologica Japonica, 1994, 103 3: 121-135. DOI:
10.1254/fpj.103.121[5] YOKO YAMAUCHI Tatsuo S Terumichi Fujikura. The Effect of H1 Antagonists Carebastine and Olopatadine on Histamine Induced Expression of CC Chemokines in Cultured Human Nasal Epithelial Cells[J]. Allergology International, 2007, 56 2: Pages 171-177. DOI:
10.2332/allergolint.o-06-446